Esperion Nets Another Positive Late-Stage Study Under Its Belt

Summary

  • Esperion Therapeutics posts positive phase 2 results in patients with elevated levevels of LDL-C who were on background therapy with an injectable PCSK9 inhibitor.
  • The positive synergy between bempedoic acid and repatha may provide a path forward for other combination therapies involving PCSK9 inhibitors.
  • Positive phase 3 data in a prior study proved that bempedoic acid improved clinical outcome over placebo for those already on lipid modifying therapies.
  • The financials are solid as Esperion has enough cash to fund its operations well into 2020, meaning that other bempedoic acid trials will be read out before a cash raise is necessary.
  • The positive outcome of adding bempedoic acid together with an injectable PCSK9 inhibitor makes Esperion an attractive acquisition target.

Recently, Esperion Therapeutics (NASDAQ:ESPR) announced positive phase 2 results in patients with hypercholesterolemia. What this entails is that the company's drug bempedoic acid can be combined with injectable PCSK9 inhibitors to improve upon a patient's clinical outcome. That's because sometimes even when these patients take a PCSK9 inhibitor alone, it does not lower their cholesterol enough to be effective. That's why I believe that this new data is solid and why Esperion Therapeutics remains a solid buy.

Phase 2 Data

The phase 2 study was to evaluate the safety and efficacy of 180 mg/day bempedoic acid in patients with hypercholesterolemia (high cholesterol) who were already taking a PCSK9 inhibitor. This entailed 59 patients being randomized to receive either bempedoic acid or placebo as an add on therapy to a PCSK9 inhibitor. The primary endpoint of the study was to determine the eight-week LDL-C lowering efficacy of bempedoic acid versus placebo while patients were on a PCSK9 inhibitor. More specifically, patients were on a background therapy of Amgen (AMGN) repatha. The results were really good, as the trial met on its primary endpoint of achieving significantly better LDL-C lowering compared to placebo. It was noted that patients treated with bempedoic acid achieved a 27% decrease in LDL levels, compared to the placebo patients who had instead seen an increase of 3% in LDL. The results are outstanding but there is something else of importance that was observed in the study. The patients treated with bempedoic acid had achieved a 34% drop in high-sensitivity C-reactive protein (hsCRP). This compares to the placebo which only achieved a 2% reduction of the hsCRP biomarker. Why is this hsCRP biomarker so important? That's because this biomarker, which deals with inflammation, is linked to heart disease. The greater the reduction observed with respect to this biomarker, the greater the reduced risk of heart disease.

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical investment research service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to my Service, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers deep dive analysis of many pharmaceutical companies throughout the biotech sector. Come see for yourself if my service is right for you.


Pricing: The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.


Author's note: To get these types of premium articles on attractive biotech and pharma stocks as soon as they are published, just click here for my profile. Hit the big orange "Follow" button and choose the real-time alerts option thank you for taking the time to read my analysis.

This article was written by

Terry Chrisomalis profile picture
10.62K Followers
Actionable ideas on small-large cap biotech stocks through deep analysis.

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.